Literature DB >> 17661091

Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.

Gian Marco Ghiggeri1, Luca Musante, Giovanni Candiano, Maurizio Bruschi, Laura Santucci, Giancarlo Barbano, Antonella Trivelli, Lucia Rivabella, Rosanna Gusmano, Francesco Perfumo.   

Abstract

We describe a child presenting with oligoclonal plasma IgM (1.2 g%) and nephrotic syndrome with focal segmental glomerulosclerosis. Oligoclonality was demonstrated by the analysis of the complementary determining region 3 (CDR 3) on immunoglobulin heavy chains and by two dimensional electrophoresis and Western blot analysis that showed the bulk of isoforms having a cationic muU chain compared with the normal homologue (pI 7.5 vs 6.5). Urinary light chains were absent, and bone marrow aspirate was normal. Usual therapies for nephrotic syndrome with steroids and cyclosporin were useless. At the age of 9 years the patient was treated with plasmapheresis plus cyclophosphamide (2 mg/kg per day for 60 days), which temporarily reduced plasma IgM, and proteinuria was normal for 3 years. After this period, due to new recurrence of nephrotic syndrome, the patient received a cycle with anti-CD20 antibodies (500 mg/m(2) every week for a month) associated with a cycle of plasmapheresis that normalized proteinuria again, and, after 3 years, the proteinuria is still in remission. This is the first case of nephrotic syndrome associated with oligoclonal plasma IgM and mesangial IgM deposits. Both cyclophosphamide and anti-CD20 antibodies associated with plasmapheresis induced, at different stages, stable and protracted remission of proteinuria without evident side effects. Long term efficacy and safety of the association are still to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661091     DOI: 10.1007/s00467-007-0550-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  T cells and minimal change disease.

Authors:  Robyn Cunard; Carolyn J Kelly
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

2.  Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?

Authors:  Stephen D Marks; Mary McGraw
Journal:  Pediatr Nephrol       Date:  2006-08-26       Impact factor: 3.714

Review 3.  Primary focal segmental glomerulosclerosis.

Authors:  S M Korbet
Journal:  J Am Soc Nephrol       Date:  1998-07       Impact factor: 10.121

Review 4.  Distinguishing minimal-change disease from mesangial disorders.

Authors:  W A Border
Journal:  Kidney Int       Date:  1988-09       Impact factor: 10.612

5.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

6.  The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change.

Authors:  A J McAdams; R P Valentini; T R Welch
Journal:  Medicine (Baltimore)       Date:  1997-01       Impact factor: 1.889

7.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

8.  Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children.

Authors: 
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

9.  Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  Kidney Int       Date:  1981-12       Impact factor: 10.612

10.  Effect of chronic administration of different Bence Jones proteins on rat kidney.

Authors:  P Smolens; J L Barnes; J H Stein
Journal:  Kidney Int       Date:  1986-12       Impact factor: 10.612

View more
  1 in total

1.  Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Authors:  Alessia Fornoni; Junichiro Sageshima; Changli Wei; Sandra Merscher-Gomez; Robier Aguillon-Prada; Alexandra N Jauregui; Jing Li; Adela Mattiazzi; Gaetano Ciancio; Linda Chen; Gaston Zilleruelo; Carolyn Abitbol; Jayanthi Chandar; Wacheree Seeherunvong; Camillo Ricordi; Masami Ikehata; Maria Pia Rastaldi; Jochen Reiser; George W Burke
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.